Over-the-Counter Hearing Aid Act of 2017

Last updated
Over the Counter Hearing Aid Act of 2017
Great Seal of the United States (obverse).svg
Long titleFDA Reauthorization Act of 2017 SEC. 709. Regulation of Over-the-Counter Hearing Aids.
Acronyms (colloquial)OTC Hearing Aid Act
Enacted bythe 115th United States Congress
EffectiveAugust 18, 2017
Citations
Public law 115-52 Sec 709
Codification
Acts amended Federal Food, Drug and Cosmetic Act
Titles amended 21 U.S.C.: Food and Drugs
Legislative history

The Over-the-Counter Hearing Aid Act of 2017 (OTC Hearing Aid Act) was a law passed by the 115th United States Congress as a rider on the FDA Reauthorization Act of 2017. It created a class of hearing aids regulated by the Food and Drug Administration (FDA) available directly to consumers without involvement from a licensed professional (like an audiologist, otolaryngologist, or audiometrist). [1] Regulations for this new class of hearing aid are expected to be released by the end of 2020. [2]

Contents

History

Hearing loss affects approximately 466 million individuals worldwide and is most concentrated among older adults. [3] Approximately half of adults in the US age 60+ have some degree of hearing loss. [4] Despite hearing loss' impact on communication, social functioning, and economic productivity across the life course, [3] hearing aid uptake is no higher than 50% - even in settings where costs are covered by insurance. [5] Barriers to addressing hearing loss in the U.S. include stigma, financial costs, and navigating a confusing array of healthcare providers and products to diagnose and treat hearing impairment. [5] In the years leading up to the OTC Hearing Aid Act, the U.S. Institute of Medicine, U.S. National Academies of Science, Engineering and Medicine, President's Council of Advisors on Science and Technology, and U.S. Federal Trade Commission convened committees and workshops examining interventions to increase awareness of hearing loss as a public health problem, and improve access to acceptable, safe, and effective treatment options. From these workshops, allowing direct sale of regulated hearing aids produced by consumer electronics companies emerged as a strategy to promote increased access to hearing loss treatments. [5] [6] [7] [8] In March 2017, Representative Joe Kennedy III (D–MA) and Senator Elizabeth Warren (D–MA) introduced Over-the-Counter Hearing Aid bills in the U.S. House of Representatives and Senate, respectively. [9] [10] These bills were incorporated into the FDA Reauthorization Act of 2017 which was ratified in August 2017. [1]

Provisions

The law defined the newly created category of OTC hearing aids as devices using air conduction and/or wireless air conduction to improve hearing among adults with "perceived mild to moderate hearing impairment." [1] Devices that modify or amplify sound for people with normal hearing (like noise-cancelling headphones or game ears) are not classified as OTC hearing aids. To ensure safety and effectiveness, the FDA was charged with developing functional guidelines; labeling and marketing standards; and conditions of sale. The Act required the U.S. Department of Health and Human Services to document adverse events associated with OTC hearing aids. The FDA was further tasked with implementing rules regarding the extent of pre-marketing approval required before OTC hearing aids can be sold commercially. [1]

Implementation

In October 2018, the FDA approved the first regulated direct-to-consumer hearing aid, the Bose Hearing Aid, under de-novo premarket review pathway provisions established in the Food and Drug Administration Modernization Act of 1997 and 21st Century Cures Act; regulations under the OTC Hearing Aid Act were not yet published. [11] [12] One year later, the FDA deemed certain Class I and Class II hearing aid-related diagnostic tests and devices exempt from 510(k) pre-market notification requirements. [13] The entry of additional regulated OTC hearing aids, and evaluation of adverse events associated with these devices were to be forthcoming. Regulations for the new class of hearing aid were originally supposed to be released by August 2020, but the FDA delayed them reportedly due to efforts focusing on COVID-19. The new deadline for the release of regulations was expected to be the end of 2020. [2]

Reception

The OTC Hearing Aid Act provisions were met with both support and concern regarding their effects on consumer safety, patient care, and hearing-related professions. Some advocacy organizations, consumer electronics companies, and trade organizations supported the Act, citing telehealth advances, [14] competitive pricing, and recent device improvements as opportunities [15] to widen access to hearing loss treatments. [16] [17] At the same time, the absence of a clear regulatory pathway detailing manufacturing, safety, and effectiveness standards for OTC hearing aids was raised as a barrier to successful roll-out of OTC hearing devices. [18] [19]

Detractors maintained that the current unmet need in hearing loss treatments will not be met by regulating OTC hearing devices. [20] Members of the public and hearing-related professional organizations expressed concerns over the prudence of creating a potentially sub-par class of devices in the absence of evidenced-based practices in patient-directed diagnosis and treatment. [21] [22] [23] Critics also charged that given their lower level of regulation, OTC devices have greater potential to be misused and damage brain function. [24] Critics also noted that in its current form, the Act omits support from licensed professionals, which has been found to improve patient satisfaction and product retention. [25] [19] [26] Patient advocates noted that the Act does nothing for individuals with moderately-severe to profound hearing loss. Additionally, it was proposed that the creation of an OTC hearing device class may motivate insurance carriers to drop hearing aid coverage altogether. [27]

See also

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">Over-the-counter drug</span> Medication available without a prescription

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription. In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products. By regulating APIs instead of specific drug formulations, governments allow manufacturers the freedom to formulate ingredients, or combinations of ingredients, into proprietary mixtures.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is only permitted to be dispensed to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases.The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.

<span class="mw-page-title-main">Cliff Stearns</span> American businessman and politician

Clifford Bundy Stearns Sr. is an American businessman and politician who was the U.S. representative for Florida's 6th congressional district from 1989 to 2013. He is a member of the Republican Party.

<span class="mw-page-title-main">Hearing aid</span> Electroacoustic device

A hearing aid is a device designed to improve hearing by making sound audible to a person with hearing loss. Hearing aids are classified as medical devices in most countries, and regulated by the respective regulations. Small audio amplifiers such as personal sound amplification products (PSAPs) or other plain sound reinforcing systems cannot be sold as "hearing aids".

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

<span class="mw-page-title-main">Federal Food, Drug, and Cosmetic Act</span> Acts of the United States Congress

The United States Federal Food, Drug, and Cosmetic Act is a set of laws passed by the United States Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, medical devices, and cosmetics. A principal author of this law was Royal S. Copeland, a three-term U.S. senator from New York. In 1968, the Electronic Product Radiation Control provisions were added to the FD&C. Also in that year the FDA formed the Drug Efficacy Study Implementation (DESI) to incorporate into FD&C regulations the recommendations from a National Academy of Sciences investigation of effectiveness of previously marketed drugs. The act has been amended many times, most recently to add requirements about bioterrorism preparations.

<span class="mw-page-title-main">Medical device</span> Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

Service and supports for people with disabilities are those government or other institutional services and supports specifically provided to enable people who have disabilities to participate in society and community life. Some such services and supports are mandated or required by law, some are assisted by technologies that have made it easier to provide the service or support while others are commercially available not only to persons with disabilities, but to everyone who might make use of them.

Sonova Holding AG is an internationally active Swiss group of companies headquartered in Stäfa that specializes in hearing care. The Sonova group operates through its core business brands Phonak, Unitron, Hansaton, Advanced Bionics, AudioNova and Sennheiser. It is one of the largest providers in the sector worldwide. The group and its brands hold 24% of the global hearing aid market in sales. As of 11 September 2022, Sonova is a component of the Swiss Market Index.

<span class="mw-page-title-main">Margaret Hamburg</span> American public health administrator

Margaret Ann "Peggy" Hamburg is an American physician and public health administrator, who is serving as the chair of the board of the American Association for the Advancement of Science (AAAS) and co-chair of the InterAcademy Partnership (IAP). She served as the 21st Commissioner of the U.S. Food and Drug Administration from May 2009 to April 2015.

This article is about the history of the United States Food and Drug Administration.

Personal Sound Amplification Products, also known as "Personal Sound Amplification Devices," or by the acronym PSAP, are defined by the U.S. Food and Drug Administration as wearable electronic products that are intended to amplify sounds for people who are not d/Deaf or Hard of Hearing. They are not hearing aids, which the FDA describes as intended to compensate for hearing loss. According to Dr. Mann of the FDA, choosing a PSAP as a substitute for a hearing aid can lead to more damage to your hearing.

TINA.org (TruthinAdvertising.org) is an independent, non-profit, advertising watchdog organization. TINA.org was founded in 2012 and received its initial funding from Karen Pritzker and Michael Vlock through their Seedlings Foundation, which supports programs that nourish the physical and mental health of children and families, and fosters an educated and engaged citizenship. TINA.org is headed by Bonnie Patten, who has served as its Executive Director since its founding.

Sound World Solutions, Inc. designs, manufactures and markets Personal Sound Amplification Products and Hearing Aids that also function as Bluetooth devices. Sound World Solutions is based in Park Ridge, Illinois.

<span class="mw-page-title-main">Starkey Hearing Technologies</span> American company

Starkey Hearing Technologies is an American privately owned company based in Eden Prairie, Minnesota that makes hearing aids, and is one of the largest hearing aid manufacturers in the world. As of 2019, the company had more than 5,000 employees in 24 facilities, serving more than 100 markets worldwide, and is the only American-owned global hearing aid manufacturer.

The distribution of medications has special drug safety and security considerations. Some drugs require cold chain management in their distribution.

In sound technology, personal sound refers to a range of software solutions that customize an audio device's sound output to match the listener's unique hearing sensitivities. The technologies aim to optimize the sound quality in the audio device to ensure they best fit the hearing perception of each unique listener.

Treatment depends on the specific cause if known as well as the extent, type, and configuration of the hearing loss. Most hearing loss results from age and noise, is progressive, and irreversible. There are currently no approved or recommended treatments to restore hearing; it is commonly managed through using hearing aids. A few specific types of hearing loss are amenable to surgical treatment. In other cases, treatment involves addressing underlying pathologies, but any hearing loss incurred may be permanent.

References

  1. 1 2 3 4 "H.R.2430 - 115th Congress (2017-2018): FDA Reauthorization Act of 2017". www.congress.gov. 2017-08-18. Retrieved 2020-03-16.{{cite web}}: CS1 maint: url-status (link)
  2. 1 2 "Delayed Release of Proposed Over-the-Counter Hearing Aid Regulations". American Academy of Audiology. 2020-08-19. Archived from the original on 2020-09-21. Retrieved 2020-10-05.
  3. 1 2 "Deafness and hearing loss". www.who.int. Retrieved 2020-03-16.
  4. ↑ "Public Health and Scientific Information | NCEH | CDC". www.cdc.gov. 2019-10-04. Retrieved 2020-03-16.
  5. 1 2 3 National Academies of Sciences, Engineering (2016-06-02). Hearing Health Care for Adults: Priorities for Improving Access and Affordability. ISBN   978-0-309-43926-8.
  6. ↑ Institute of Medicine and National Research Council (January 14, 2014). Hearing Loss and Healthy Aging: Workshop Summary. doi:10.17226/18735. ISBN   978-0-309-30226-5. PMID   24872992 . Retrieved March 16, 2019.{{cite book}}: CS1 maint: url-status (link)
  7. ↑ President's Council of Advisors on Science and Technology (October 26, 2015). "Aging America & Hearing Loss: Imperative of Improved Hearing Technologies" (PDF). Retrieved March 16, 2019.{{cite web}}: CS1 maint: url-status (link)
  8. ↑ Federal Trade Commission (2017-01-03). "Now Hear This: Competition, Innovation, and Consumer Protection Issues in Hearing Health Care" . Retrieved 2020-03-16.{{cite web}}: CS1 maint: url-status (link)
  9. ↑ "Actions - H.R.1652 - 115th Congress (2017-2018): Over-the-Counter Hearing Aid Act of 2017". www.congress.gov. 2017-03-24. Retrieved 2020-03-16.
  10. ↑ "Actions - S.670 - 115th Congress (2017-2018): Over-the-Counter Hearing Aid Act of 2017". www.congress.gov. 2017-03-21. Retrieved 2020-03-16.{{cite web}}: CS1 maint: url-status (link)
  11. ↑ U.S. Food and Drug Administration (2018-10-05). "FDA allows marketing of first self-fitting hearing aid controlled by the user". FDA. Retrieved 2020-03-16.{{cite web}}: CS1 maint: url-status (link)
  12. ↑ U.S. Food and Drug Administration (November 20, 2019). "De Novo Classification Request". Food and Drug Administration . Retrieved March 16, 2020.{{cite web}}: CS1 maint: url-status (link)
  13. ↑ "Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices". Federal Register. 2019-12-30. Retrieved 2020-03-16.
  14. ↑ TWo Pi GmbH (2017-05-22). "Hearing Health and Technology -- Workshop, Project No. P171200 #00130". Federal Trade Commission. Archived from the original on 2020-09-19. Retrieved 2020-03-16.
  15. ↑ Cellular Telecommunications Industry Association (CTIA) (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00134". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  16. ↑ Consumer Technology Association (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00133". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  17. ↑ Hearing Loss Association of America (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00136". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  18. ↑ Bose Corporation (May 18, 2017). "Hearing Health and Technology Workshop Project No. P171200" (PDF). Archived from the original (PDF) on April 2, 2021. Retrieved March 16, 2020.
  19. 1 2 Lynn, Deborah (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00132". Federal Trade Commission. Archived from the original on 2020-09-24. Retrieved 2020-03-16.
  20. ↑ Stewart, Cynthia (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00131". Federal Trade Commission. Archived from the original on 2020-09-19. Retrieved 2020-03-16.
  21. ↑ Richard, Hammers (2017-05-19). "Hearing Health and Technology -- Workshop, Project No. P171200 #00142". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  22. ↑ Segev, Melissa (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00137". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  23. ↑ Well, Barbara (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00139". Federal Trade Commission. Archived from the original on 2020-09-24. Retrieved 2020-03-16.
  24. ↑ Butterfield, Melissa (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00128". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  25. ↑ Hammers, Chantal (2017-05-22). "Hearing Health and Technology -- Workshop, Project No. P171200 #00141". Federal Trade Commission. Archived from the original on 2020-09-24. Retrieved 2020-03-16.
  26. ↑ Crosby, Noel (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00135". Federal Trade Commission. Archived from the original on 2020-09-18. Retrieved 2020-03-16.
  27. ↑ Michaels, Michele (2017-05-18). "Hearing Health and Technology -- Workshop, Project No. P171200 #00138". Federal Trade Commission. Archived from the original on 2020-09-24. Retrieved 2020-03-16.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.